• LAST PRICE
    2.4100
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (1.2605%)
  • Bid / Lots
    2.3500/ 10
  • Ask / Lots
    2.4800/ 5
  • Open / Previous Close
    2.4000 / 2.3800
  • Day Range
    Low 2.3500
    High 2.5300
  • 52 Week Range
    Low 1.2600
    High 6.8600
  • Volume
    315,734
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.39
TimeVolumeADAP
09:32 ET114712.425
09:36 ET10002.43
09:38 ET14002.41
09:39 ET21392.39
09:41 ET129732.42
09:43 ET47982.38
09:45 ET19492.38
09:48 ET66242.42
09:50 ET6002.42
09:52 ET12002.39
09:57 ET6582.42
09:59 ET8002.41
10:03 ET9462.406
10:08 ET5002.4068
10:10 ET7002.3993
10:14 ET25002.3949
10:15 ET11002.4077
10:17 ET1002.38
10:19 ET10002.37
10:21 ET3502.365
10:24 ET66402.352
10:26 ET2002.37
10:30 ET2002.38
10:33 ET8002.4
10:35 ET1002.4
10:37 ET1002.405
10:39 ET2202.3942
10:42 ET3002.42
10:46 ET10012.425
10:48 ET8002.44
10:50 ET1732.44
10:51 ET20322.42
10:53 ET6002.43
10:55 ET42122.46
10:57 ET14002.47
11:00 ET28122.45
11:02 ET5252.4657
11:04 ET123002.5299
11:06 ET61712.515
11:08 ET10002.5299
11:09 ET88432.5
11:11 ET10002.507
11:13 ET2002.5001
11:15 ET45082.47
11:18 ET2002.477
11:22 ET1002.47
11:24 ET2002.46
11:27 ET14132.49
11:31 ET8002.49
11:33 ET57002.5
11:36 ET14492.51
11:38 ET145792.46
11:40 ET22002.465
11:42 ET3182.47
11:45 ET14282.47
11:47 ET6002.48
11:49 ET1002.48
11:54 ET1002.48
11:58 ET1002.48
12:00 ET19002.4688
12:12 ET2002.455
12:21 ET1002.455
12:23 ET1002.44
12:27 ET1002.4552
12:30 ET52852.44
12:32 ET5002.44
12:34 ET1002.45
12:36 ET1002.45
12:38 ET6742.4594
12:39 ET55262.46
12:50 ET6472.46
12:52 ET93412.45
12:54 ET2162.45
12:56 ET1002.455
12:59 ET1002.47
01:01 ET1002.47
01:03 ET1002.455
01:06 ET4002.4442
01:08 ET1492.4466
01:10 ET1002.455
01:12 ET5002.47
01:14 ET11002.46
01:21 ET66362.45
01:24 ET2002.44
01:26 ET33662.42
01:28 ET42622.415
01:30 ET3002.42
01:32 ET2002.415
01:33 ET1002.415
01:35 ET2002.415
01:37 ET2002.4186
01:39 ET3782.415
01:46 ET2572.415
01:48 ET1002.415
01:50 ET1002.415
01:51 ET4082.415
01:55 ET16352.41
01:57 ET5112.42
02:00 ET1002.42
02:02 ET2002.415
02:06 ET5242.415
02:08 ET3152.415
02:09 ET3372.4153
02:11 ET5122.42
02:13 ET2002.42
02:15 ET149552.405
02:18 ET4002.405
02:22 ET23892.415
02:29 ET16962.4127
02:31 ET7392.42
02:36 ET1002.42
02:38 ET2002.42
02:40 ET71222.395
02:42 ET1002.395
02:44 ET3002.3952
02:45 ET17452.4
02:49 ET8412.405
02:54 ET1002.39
03:00 ET9052.405
03:02 ET1002.4
03:03 ET1002.39
03:09 ET2002.39
03:16 ET2002.405
03:18 ET1002.4125
03:20 ET8002.405
03:23 ET8002.39
03:27 ET6502.405
03:30 ET2002.405
03:32 ET7122.41
03:34 ET11642.425
03:36 ET4002.425
03:38 ET40082.415
03:39 ET9712.415
03:41 ET14002.415
03:43 ET16252.42
03:45 ET3002.415
03:48 ET9002.41
03:50 ET51002.415
03:52 ET13232.43
03:54 ET29512.41
03:56 ET46152.4
03:57 ET143362.41
03:59 ET154792.41
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADAP
Adaptimmune Therapeutics PLC
375.8M
-2.2x
---
United StatesABSI
Absci Corp
390.0M
-3.5x
---
United StatesZOM
Zomedica Corp
377.3M
-19.7x
---
United StatesABUS
Arbutus Biopharma Corp
374.9M
-4.2x
---
United StatesHUMA
Humacyte Inc
359.5M
-18.9x
---
United StatesTRDA
Entrada Therapeutics Inc
395.5M
0.0x
---
As of 2022-08-15

Company Information

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and have reported clinical responses (per RECIST 1.1) in seven solid tumor indications. Its platform enables to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors; Tumor Infiltrating Lymphocytes (TiLs) where a patient’s own T-cells are co-administered with its next generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its clinical trials include Spearhead-1 Phase II trial with afamitres gene autoleucel; Surpass Phase I Trial with ADP-A2M4CD8, and others.

Contact Information

Headquarters
60 Jubilee AvenueABINGDON, United Kingdom OX14 4RX
Phone
123-543-0000
Fax
---

Executives

Non-Executive Independent Chairman of the Board
David Mott
Chief Executive Officer, Director
Adrian Rawcliffe
Chief Financial Officer
Gavin Wood
Chief Operating Officer
William Bertrand
Chief Scientific Officer
Joanna Brewer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$375.8M
Revenue (TTM)
$11.7M
Shares Outstanding
163.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.81
EPS
$-1.12
Book Value
$1.32
P/E Ratio
-2.2x
Price/Sales (TTM)
32.0
Price/Cash Flow (TTM)
---
Operating Margin
-1,523.72%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.